Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy
January 24th, 2010 Posted in hormone therapy, radiation therapyDiscrepancies exist regarding the impact of neoadjuvant hormone therapy (NHT) on the risk of all-cause mortality (ACM) in men who receive brachytherapy for localized prostate cancer. Therefore, the latest study at Harvard Radiation Oncology Program, Boston, Massachusetts targeted to examine the effect of NHT on the risk of ACM in men with prostate cancer who receive with brachytherapy.
The study cohort included 2474 men with localized prostate cancer who either received NHT (N = 1083) or did not receive NHT (N = 1391) and brachytherapy without supplemental external beam radiation between 1991 and 2005 at centers within the 21st Century Oncology Consortium. All men had at least 2 years of follow-up.
Researchers found that compared with men who were younger than the median age of 73 years, men aged >/=73 years with localized prostate cancer who received brachytherapy and NHT had an increased risk of ACM compared with men who did not receive NHT.